Antisense Therapeutics logo

ANP - Antisense Therapeutics Share Price

A$0.068 -0.0  -2.9%

Last Trade - 5:10am

Sector
Healthcare
Size
Micro Cap
Market Cap £15.2m
Enterprise Value £13.7m
Revenue £34.3k
Position in Universe 1064th / 1831
Bullish
Bearish
Unlock ANP Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ANP Revenue Unlock ANP Revenue

Net Income

ANP Net Income Unlock ANP Revenue

Normalised EPS

ANP Normalised EPS Unlock ANP Revenue

PE Ratio Range

ANP PE Ratio Range Unlock ANP Revenue

Dividend Yield Range

ANP Dividend Yield Range Unlock ANP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ANP EPS Forecasts Unlock ANP Revenue
Profile Summary

Antisense Therapeutics Limited (ANP) is an Australia-based pharmaceutical drug discovery and development company. The Company is engaged in the research and development of antisense pharmaceuticals. The Company's product candidate, ATL1103, is an antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood. ATL1103 is in clinical development for acromegaly, diabetic retinopathy and diabetic nephropathy. The Company's product candidate, ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. The Company completed a Phase IIa efficacy and safety trial of ATL1102 in multiple sclerosis (MS) patients. The Company's product candidate, ATL1101, is an antisense inhibitor of insulin like growth factor 1 receptor (IGF-Ir). It is developing ATL1101 for the treatment of prostate cancer. It is also developing ATL1102 as an inhaled treatment for asthma.

Directors
Last Annual June 30th, 2019
Last Interim June 30th, 2019
Incorporated November 13, 2000
Public Since December 20, 2001
No. of Shareholders: n/a
No. of Employees: 8
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 420,103,487
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ANP Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ANP
Upcoming Events for ANP
Similar to ANP
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.